leisure time -WSS

leisure time

author：comprehensive 2025-10-01 21:40:22 - browse：8

Anna Yeo/STAT

Recently approved gene therapies offer patients one-time, potentially curative treatments for genetic diseases such as sickle cell anemia and beta thalassemia. But “one-time” miracle solutions can often be multi-month affairs, require millions of dollars, and cause painful side effects. What if that doesn’t have to be the case?

In utero gene editing, or prenatal somatic cell genome editing, envisions treating a fetus diagnosed with a genetic disease before birth, thereby preventing that entire protocol and the onset of symptoms in the first place. It would also challenge the need for the ethically fraught enterprise of embryo editing, as the treatment would only make edits in the DNA of the individual fetus — edits which would not be passed on in a heritable way.

Watch this video to learn more about in utero gene editing, how it works, and why scientists believe it might be an advantageous approach to treating certain genetic diseases.

Previous article： The high cost of giving birth even with insurance
Next article： How a scoliosis diagnosis changed the life of one young dancer

leisure time

WSS

The biotech scorecard for Q1: 17 stock

As Maui death toll rises, number of missing remains unclear

JPM: CVS says Medicare Advantage patients are impacting profits

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

3 medical device trends to watch in 2024

Ahead of JPM, here's who's profiting most in health care

Wikipedia

leisure time

entertainment

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

3 medical device trends to watch in 2024

BioMarin wins approval for gene therapy to treat hemophilia A

Ahead of JPM, here's who's profiting most in health care

How one medical school became remarkably diverse

How a scoliosis diagnosis changed the life of one young dancer

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Feng Zhang, Grail founder join forces on new gene editing startup

Alkermes shareholders re

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

hotspot

GSK Flovent asthma inhalers replaced by authorized generics

A single drug, study failures leave Anavex with nothing but cash

JPM: CVS says Medicare Advantage patients are impacting profits

J&J to buy cancer drug developer Ambrx Biopharma

Evacuations in place as 3 wildfires burn in eastern Washington state

Cancer drug shortages' outsize impact on ovarian cancer patients

hotspot

entertainment

leisure time

knowledge